EXEL Share Price

Open 18.12 Change Price %
High 18.29 1 Day 0.42 2.36
Low 17.78 1 Week 1.32 7.80
Close 18.25 1 Month 5.89 47.65
Volume 6459192 1 Year 13.09 253.68
52 Week High 18.29
52 Week Low 3.55
EXEL Important Levels
Resistance 2 18.72
Resistance 1 18.53
Pivot 18.11
Support 1 17.97
Support 2 17.78
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
WRES 0.09 0.00%
SIRI 4.41 1.85%
QQQ 116.87 0.23%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
ECTE 0.14 40.00%
BNSO 3.57 31.25%
FRAN 20.01 28.76%
FRAN 20.01 28.76%
FRAN 20.01 28.76%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
CRDS 5.45 25.87%
OTT 2.39 25.13%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
IMRS 0.02 -33.33%
More..

Exelixis, Inc. (NASDAQ: EXEL)

EXEL Technical Analysis 5
As on 6th Dec 2016 EXEL Share Price closed @ 18.25 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 8.33 & Strong Buy for SHORT-TERM with Stoploss of 13.88 we also expect STOCK to react on Following IMPORTANT LEVELS.
EXEL Target for December
1st Target up-side 20.94
2nd Target up-side 23.74
3rd Target up-side 26.55
1st Target down-side 12.92
2nd Target down-side 10.12
3rd Target down-side 7.31
EXEL Other Details
Segment EQ
Market Capital 726558528.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.exelixis.com
EXEL Address
EXEL
210 East Grand Avenue
South San Francisco, CA 94080
United States
Phone: 650-837-7000
Fax: 650-837-8300
Interactive Technical Analysis Chart Exelixis, Inc. ( EXEL NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Exelixis, Inc.
EXEL Business Profile
Exelixis, Inc. (Exelixis) is a biotechnology company engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing its resources and development efforts on cabozantinib (XL184). It also has a portfolio of other compounds. Cabozantinib is the inhibitor of MET in clinical development and is being evaluated in a development program encompassing multiple cancer indications. The clinical program for cabozantinib is focused on the treatment of metastatic castration-resistant prostate cancer (CRPC) and medullary thyroid cancer but also includes the evaluation of other tumor types. Cabozantinib inhibits MET, VEGFR2 and RET, proteins that are key drivers of tumor growth, vascularization and/or metastasis.